- Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit
-
Kandeel M, Yamamoto M, Tani H, Kobayashi A, Gohda J, Kawaguchi Y, Park BK, Kwon HJ, Inoue Ji, Alkattan A
- KMID: 2515276
- Biomol Ther.
- 2021 May;29(3):282-289.
- doi: 10.4062/biomolther.2020.201
A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the... -
- CITED
-
- Close
- SHARE
-
- Close
- Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein
-
Kim J, Hwang SY, Kim D, Kim M, Baek K, Kang M, An S, Gong J, Park S, Kandeel M, Lee Y, Noh M, Kwon HJ
- KMID: 2532875
- Biomol Ther.
- 2022 Sep;30(5):427-434.
- doi: 10.4062/biomolther.2022.037
The drug repurposing strategy has been applied to the development of emergency COVID-19 therapeutic medicines. Current drug repurposing approaches have been directed against RNA polymerases and viral proteases. Recently, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Small Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Fusion by Targeting Cavities on Heptad Repeat Trimers
-
Kandeel M, Yamamoto M, Al-Taher A, Watanabe A, Oh-hashi K, Park BK, Kwon HJ, Inoue Ji, Al-Nazawi M
- KMID: 2503470
- Biomol Ther.
- 2020 Jul;28(4):311-319.
- doi: 10.4062/biomolther.2019.202
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a newly emerging viral disease with fatal outcomes. However, no MERS-CoV-specific treatment is commercially available. Given the absence of previous structure-based drug discovery... -
- CITED
-
- Close
- SHARE
-
- Close
